Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2017

01-08-2017 | REVIEW

Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis

Authors: Giandomenico Roviello, Chiara Pacifico, Paola Corona, Daniele Generali

Published in: Investigational New Drugs | Issue 4/2017

Login to get access

Summary

Ramucirumab is a monoclonal antibody against Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) approved for the treatment of several solid tumours. As shown in recent trials results, new-onset hypertension is one of the most frequent adverse events associated with ramucirumab therapy. Recent studies looked at the quantification of the risk of hypertension in patients receiving other anti-angiogenesis medications. We conducted a meta-analysis of randomized clinical trials with the aim to investigate the incidence and quantify the risk of new-onset hypertension of any grade in patients treated with ramucirumab. Our research suggests that hypertension is frequently associated with ramucirumab therapy, with an OR of 3.60 for any grade of hypertension and an even stronger correlation with grade 3–4 hypertension (OR 4.16). These data suggest that a strict monitoring, as well as early intervention protocols, are recommended in patients receiving the drug.
Appendix
Available only for authorised users
Literature
1.
2.
Spratlin JL, Cohen RB, Eadens M et al (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28:780–787CrossRefPubMedPubMedCentral
3.
Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383(9911):31–39CrossRefPubMed
4.
Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11):1224–1235CrossRefPubMed
5.
Roviello G, Polom K, Petrioli R et al (2016) Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. Tumour Biol 37(1):127–40
6.
Garon EB, Ciuleanu TE, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384(9944):665–673CrossRefPubMed
7.
Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 16(5):499–508CrossRefPubMed
8.
Zhu AX, Park JO, Ryoo B et al (2015) Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 16(7):859–870CrossRefPubMed
9.
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) PRISMA Group PRISMA Group preferred reporting items for systematic reviews and meta-analyses: the prisma statement. PLoS Med 6:e1000097CrossRefPubMedPubMedCentral
10.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12CrossRefPubMed
11.
12.
Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129CrossRef
13.
14.
Yoon HH, Bendell JC, Braiteh FS et al (2016) Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter phase II trial. Ann Oncol 27(12):2196–2203
15.
Moore M, Gill S, Asmis T et al (2016) Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. Ann Oncol 27(12):2216–2224
16.
Yoh K, Hosomi Y, Kasahara K et al (2016) A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer 99:186–193CrossRefPubMed
17.
Fraeman KH, Nordstrom BL, Luo W et al (2013) Incidence of new-onset hypertension in cancer patients: a retrospective cohort study. Int J Hyperts 2013 :10Article ID 379252
18.
Chen J, Lu Y, Zheng Y (2015) Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 9:4751–4760PubMedPubMedCentral
19.
Qu CY, Zheng Y, Zhou M, Zhang Y, Shen F, Cao J, Xu LM (2015) Value of bevacizumab in treatment of colorectal cancer: a meta-analysis. World J Gastroenterol 21(16):5072–5080CrossRefPubMedPubMedCentral
20.
Dionísio de Sousa IJ, Ferreira J, Rodrigues J et al (2016) Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer. ESMO Open 1(3):e000045CrossRefPubMedPubMedCentral
Metadata
Title
Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis
Authors
Giandomenico Roviello
Chiara Pacifico
Paola Corona
Daniele Generali
Publication date
01-08-2017
Publisher
Springer US
Published in
Investigational New Drugs / Issue 4/2017
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-017-0452-1

Other articles of this Issue 4/2017

Investigational New Drugs 4/2017 Go to the issue

Erratum

Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients

REVIEW

Lung cancer and β-glucans: review of potential therapeutic applications

PHASE I STUDIES

Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II

PRECLINICAL STUDIES

MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells

PHASE I STUDIES

Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study

PHASE II STUDIES

Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits